M&As this week: SELLAS Life Sciences Group, Cempra
SELLAS Life Sciences Group has signed a definitive agreement to merge with Galena Biopharma.
SELLAS will become a wholly owned subsidiary of Galena, following the completion of the merger.
SELLAS is a clinical-stage biopharmaceutical company based in Bermuda, while Galena Biopharma is a late-stage biopharmaceutical company based in the US.
Clinical-stage pharmaceutical company Cempra plans to merge with commercial-stage biopharmaceutical company, Melinta Therapeutics.
The merged entity will be known as Melinta Therapeutics.
Both companies involved in the merger are based in the US.